Search This Blog

Tuesday, June 9, 2015

Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes (NYSE:LLY)

Phase III Data Presented at the 2015 American Diabetes Association Scientific Sessions®



Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.